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Cerebral palsy is a group of persistent movements or
postural disturbances secondary to a nonprogressive
lesion in a developing brain, and is considered the main
cause of motor disability in children, affecting 1 in 500-
1000 newborns. It is the most common cause of severe
physical disability in childhood.1 Among patients with
cerebral palsy, 70% have spasticity, which is responsible
for hamstring flexion, hip adduction, and equinus foot,
resulting in variable functional disabilities. More than 50%
of patients with the disorder can walk without arm
assistance, 25% cannot walk, and 30% are mentally
impaired.2
Spasticity is a common and disabling symptom for many
patients with upper motor neuron dysfunction. It results
from interruption of inhibitory descending spinal motor
pathways. Although the pathophysiology of spasticity is
poorly  understood3, the f inal common pathway is
overact iv ity  of  the alpha motor neuron. Muscle
overactivity, one of the cardinal features of spasticity, is a
common sequel of cerebral palsy. Spasticity is responsible
for several limitations that interfere with gait, causing
variable functional disability.4
Therapy for spasticity is symptomatic with the aim of
increasing functional capacity and relieving discomfort.
Any approach to treatment should be multidisciplinary,
including physical therapy, and possibly surgery, as well as
pharmacotherapy. Since 1980, modification of spasticity
by ora ll y admin is tered drugs, in tramuscular
chemodenervation agents, intrathecally administered
drugs and surgery has become more frequent.5
A variety of oral medications have been used to diminish
the sensitivity of local nerves and muscles to control their
reactions to environmental stimuli that result in muscle
spasticity or involuntary movements. These medications
are often only of modest benefit because of undesirable
side effects6. There are newer oral agents recognized for
their potential antispasticity properties. They include
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ABSTRACT
Cerebral palsy is the most common cause of severe physical disability in childhood. Spasticity is a common and disabling
symptom for many patients with cerebral palsy. Therapy for spasticity is symptomatic with the aim of increasing functional
capacity and relieving discomfort. Spasticity treatment by orally administered drugs and intramuscular chemodenervation
agents has become more frequent. Most oral medications to treat spasticity have been inadequately studied in children,
especially those with cerebral palsy. Since its first use in pediatric patients, reported in 1993, botulinum toxin (BTX-A), a
relatively recent addition to the available medical interventions for children with cerebral palsy, has rapidly gained
acceptance as a treatment of spasticity. The clinical effects of BTX-A have been reported to include decreased spasticity
and increased range of motion. However, no consensus exists among clinicians about how an optimal dose of BTX-A should
be determined and there are no standard guidelines on doses of BTX-A in children. Doses of 2-6 U/kg with a maximum total
dose of 29 U/kg have been reported. Although there are no standard guidelines on doses in children. The current practice is
to inject BTX-A at higher doses than reported in the past. Larger dose of BTX-A  is used more frequently, which is
considered safe, more effective, and better tolerated by children. Titration of the dose of BTX-A is necessary because
muscle spasticity affects different patients in different ways. The dosage of BTX-A must be individualized for each patient.
tizanidine, clonazepam and clonidine. Tizanidine has been
studied extensively in adults with spasticity from a variety
of causes and has been found to be of proven benefit, but
not very much is known yet of its role for childhood
cerebral palsy. Most oral medications to treat spasticity
have been inadequately studied in children, especially
those with cerebral palsy.5,7
For the walking child with spastic cerebral palsy, the
objective is to counter or minimise the negative long term
effect of spasticity and weakness during the period of
growth. Simple measures of stretching, walking, and
orthot ic use can be supplemented by ora l muscle
relaxants and particularly botulinum toxin typeA . The use
of intramuscular botulinum toxin to block neuromuscular
transmission in spastic muscles has become more popular
since its initial use with pediatric patients, reported in
1 9 9 3 .8 Its prime use has been in calf muscles to
overcome dynamic equinus of the ankle in children with
hemiplegia or diplegia. The effects of botulinum toxin are
transitory and injections must be repeated every 4 to 6
months.9
With the advent of botulinum toxin type A (BTX-A) as an
adjuvant treatment of patients with equinus foot, several
studies have been reported demonstrating that BTX-A can
be one of the main tools to improve prognosis in children
with cerebral palsy. Botulinum toxin, a relatively recent
addition to the available medical interventions for children
with cerebral palsy, has rapidly gained acceptance as a
t reatment that  temporari ly reduces foca l muscle
s p a s t i c i t y1 0. The clinical effects of BTX-A have been
reported to include decreased spasticity and increased
range of motion. These effects may be critically important
when considering the influence of spasticity, limited
muscle length, and restricted range of motion on the
growing bones of young children. Controlled studies,
demonstrating the efficacy of BTX-A in treatment of
childhood cerebral palsy have led to approval for this
indication in many European countries9. The greatest
pitfalls are created by the lack of established protocols for
the walking child with spastic cerebral palsy.11,12
Doses of 2-6 U/kg body weight per muscle with a
maximum total dose of 29 U/kg have been reported.
Although there are no standard guidelines on doses in
children, a review of previous publications indicates that
the dose that has been used for children with cerebral
palsy has increased over time. The current practice is to
inject several muscles at each injection session, with
smaller patients receiving higher doses than reported in
the past.8,13
The dosage of BTX-A must be individualized for each
patient. A recent consensus statement recommended a
dose of  12 uni ts  of  Botox (Allergan,  USA) per kg
bodyweight, with a maximum of 300 units Botox per child
on one occasion, and 50 units per injection site.4 T h e
recommended treatment interval is 6-12 months, with a
minimum of 3 months. It has become apparent that larger
doses used less frequently are safe, more effective, better
tolerated by children, more acceptable to their families,
and the functional outcomes are longer lasting.14 Dosages
of 16-24 units per kg bodyweight are now in use in
experienced hands for double or triple level lower limb
sites. However, the dose-efficiency relationship might only
be linear for a distinct range. Clinicians should be aware of
unwanted effects  dur ing the application of  the
drug.11,15,16
The mean dose of BTX-A used varies between treatment
centres. This cannot be entirely explained on the basis of
different patient populations. The use of a small dose of
BTX-A may reflect a cautious attitude of the practitioner or
an attempt to reduce the cost of treatment. An alternative
explanation is that BTX-A is used in conjunction with other
antispasticity treatments. Similarly, the variability between
examiners in the evaluation of the clinical effectiveness of
BTX-A may be a factor.17,18
The clinician may inject a large dose of BTX-A to achieve a
desired reduction in muscle tone in a given patient but
may use a smaller dose in another subject, although both
patients have the same degree of muscle spasticity. This
need to titrate the dose of BTX-A is necessary because
muscle spasticity affects different patients in different
ways and the treatment decision in each case is usually
based upon therapeutic goals. The choice of therapeutic
interventions is also influenced by locally available
expertise and resources.19
Three randomised, double-blind dose-ranging studies have
examined the effects of various doses of BTX-A on gait
measures in patients with cerebral palsy. In these studies,
the higher doses of the preperations were more effective
in improving gait measures than the lower doses.1,20
What is the dose of BTX-A in cerebral palsy? There is
some debate concerning optimum treatment of BTD-A in
the non-ambulatory child. The greatest pitfalls are created
by a lack of established protocols for the walking child
with spastic cerebral palsy. There is currently no
consensus among clinicians about how an optimal dose of
BTX-A should be determined,  and there are no standard
guidelines on doses of BTX-A in children.1
There is little doubt that BTX-A has been an outstanding
advance in recent years, creating important opportunities
to enable our therapy and treatments to be significantly
more effective in the management of cerebral palsy. More
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controlled trials are now needed to confirm the anti-
spasticity effects of BTX-A with larger patients groups for
more accurate results. 
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